Suven Life Sciences will be a tonic in portfolio
Suven life sciences at Rs 170, promises to defy gravity as it has reached the bottom.
Scrip has fully bottomed out, resting on 200 Week MA.
It is also in a declining triangle, with a firm flat support between 148 ~ 163.
It needs a volume breakout, although pricewise it has reared its head up at Rs 170 now.
Catch in an infant stage is what it is presently appearing and once pharma industry develops fancy - which it should now soon anytime - with stabilisation of Trump's policies, it will race ahead dramatically.
All fundamental parameters are encouraging. Rs. 220 would be the first strong resistance and thereafter I daresay, Rs 445 may not be far away - say in a year's time frame !!!
Just Buy and hold with a stoploss of Rs 148.
Scrip has fully bottomed out, resting on 200 Week MA.
It is also in a declining triangle, with a firm flat support between 148 ~ 163.
It needs a volume breakout, although pricewise it has reared its head up at Rs 170 now.
Catch in an infant stage is what it is presently appearing and once pharma industry develops fancy - which it should now soon anytime - with stabilisation of Trump's policies, it will race ahead dramatically.
All fundamental parameters are encouraging. Rs. 220 would be the first strong resistance and thereafter I daresay, Rs 445 may not be far away - say in a year's time frame !!!
Just Buy and hold with a stoploss of Rs 148.
Clause de non-responsabilité
Les informations et les publications ne sont pas destinées à être, et ne constituent pas, des conseils ou des recommandations en matière de finance, d'investissement, de trading ou d'autres types de conseils fournis ou approuvés par TradingView. Pour en savoir plus, consultez les Conditions d'utilisation.
Clause de non-responsabilité
Les informations et les publications ne sont pas destinées à être, et ne constituent pas, des conseils ou des recommandations en matière de finance, d'investissement, de trading ou d'autres types de conseils fournis ou approuvés par TradingView. Pour en savoir plus, consultez les Conditions d'utilisation.